March 29th 2023
Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).
January 25th 2023
Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix
Mehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
FDA Grants Approval to Nivolumab as Adjuvant Treatment of Resected Esophageal/GEJ CancerMay 20th 2021
Adjuvant nivolumab for resected esophageal or gastroesophageal junction cancer was granted full approval by the FDA based on statistically significant improvements in disease-free survival over placebo in a phase 3 trial.
Analysis Correlates Cost of Therapy With Improvement in Outcomes for Patients With HCCMay 12th 2021
According to an economic evaluation, the use of atezolizumab plus bevacizumab is not cost effective versus sorafenib for the treatment of hepatocellular carcinoma when considering life-years gained and willingness-to-pay thresholds.
FDA Grants Accelerated Approval to Pembrolizumab/Trastuzumab Combination for HER2+ Gastric/GEJ CancersMay 5th 2021
Based on response data from a randomized phase 3 trial, the FDA granted accelerated approval to pembrolizumab plus trastuzumab and chemotherapy for the treatment of HER2-positive gastric tumors.
FDA Committee Does Not Support Maintaining Accelerated Approval of Nivolumab for Advanced HCCApril 30th 2021
By a close decision, the FDA’s Oncologic Drugs Advisory Committee voted against upholding the accelerated approval of nivolumab monotherapy to treat patients with hepatocellular carcinoma following sorafenib.
Adding Aprepitant Combo to Chemotherapy Regimen Reduced CINV in Women With Gastrointestinal CancerApril 27th 2021
Young women with gastrointestinal cancers who received the FOLFIRI or FOLFOX chemotherapy regimens experienced a benefit in terms of reduced nausea and vomiting with the combination of aprepitant plus palonosetron and dexamethasone.
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular CarcinomaApril 21st 2021
A thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.
FDA Grants Breakthrough Therapy Designation to Bemarituzumab for Frontline FGFR2b+ Gastric/GEJ CancersApril 20th 2021
Based on positive results of the phase 2 FIGHT trial, the FDA has granted the investigation antibody bemarituzumab plus FOLFOX6 breakthrough therapy designation for the treatment of locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma with FGFFR2b overexpression in the frontline setting.
Complete Pathological Responses Seen for Resectable HCC Treated With Neoadjuvant CemiplimabApril 17th 2021
Twenty percent of patients with resectable hepatocellular carcinoma experienced significant tumor necrosis when treated with neoadjuvant cemiplimab-rwlc, according to data from a phase 2a open label.
Addition of Nivolumab Improves OS in Patients with Unresectable, Advanced ESCCApril 8th 2021
The addition of nivolumab to either chemotherapy or ipilimumab improved overall survival among patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, according to data from the phase 3 CheckMate-648 trial.
Adjuvant Nivolumab Improves DFS in Resected Esophageal/Gastroesophageal Junction CancerMarch 24th 2021
The phase 3 CheckMate 577 trial is the first to show a checkpoint inhibitor in the adjuvant setting after trimodality therapy demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer.
FDA Grants Approval to Pembrolizumab for the Treatment of Advanced Esophageal or GEJ CarcinomaMarch 22nd 2021
Based on positive overall and progression-free survival data from the phase 3 KEYNOTE-590 trial, pembrolizumab was approved by the FDA for use in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma.
Precision Medicine Takes Center Stage in GI CancerMarch 19th 2021
In order to properly utilize cancer therapies for personalized care, adequate molecular testing must be performed in patients who are eligible for these therapies, with this necessity becoming more and more prevalent in the treatment of gastrointestinal malignancies.
Molecular Profiling and the Promise of Precision MedicineMarch 15th 2021
ONCOLOGY® sat down with John L. Marshall, MD, chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital and director of the Ruesch Center for the Cure of Gastrointestinal Cancer as well as co-chair of the 6th Annual School of Gastrointestinal Oncology® (SOGO®), hosted by Physicians' Education Resource, LLC (PER®), to discuss how personalized approaches to treating various gastrointestinal malignancies has changed the therapy landscape.
Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health InequityFebruary 23rd 2021
Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.
Adjuvant Radiotherapy Linked With Survival Benefit After Distal Cholangiocarcinoma ResectionFebruary 8th 2021
Data published in Cancer found adjuvant radiotherapy after distal cholangiocarcinoma resection was associated with a survival benefit for patients, regardless of margin or nodal status.
FDA Grants Priority Review to BLA for Retifanlimab as Possible Treatment for SCACJanuary 22nd 2021
The BLA submission is based on data observed in the phase 2 POD1UM-202 trial of retifanlimab in previously treated patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who had progressed on, or were intolerant of, standard platinum-based chemotherapy.
FDA Grants Priority Review to 2 sBLAs for Nivolumab in the Treatment of Cancers of the Gastrointestinal TractJanuary 20th 2021
Bristol Myers Squibb announced that nivolumab has been granted priority review for indications in both the first-line and adjuvant treatment settings as therapy for gastrointestinal cancers.
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric or GEJ AdenocarcinomaJanuary 15th 2021
The approval was based on results from the phase 2 DESTINY-Gastric01 trial which evaluated patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least 2 prior regimens.
Novel AI Tool Helps Patients to Find, Understand Clinical TrialsJanuary 15th 2021
Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.